{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:35:46Z","timestamp":1793230546104,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,23]]},"DOI":"10.7759\/cureus.29518","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T03:33:33Z","timestamp":1663990413000},"source":"Crossref","is-referenced-by-count":153,"title":["Overview of Methotrexate Toxicity: A Comprehensive Literature Review"],"prefix":"10.7759","author":[{"given":"Khalid M","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M","family":"Dighriri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F","family":"Baomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baidaa T","family":"Alharthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foza E","family":"Alenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadheer H","family":"Alali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan H","family":"Alenazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidaa T","family":"Alhumaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania H","family":"Alhulayfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmen B","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S","family":"Alhumaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra A","family":"Alhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhwa'a A","family":"Humadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad A","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf H","family":"Alobaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber S","year":"1948","unstructured":"Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948, 238:787-93. 10.1056\/NEJM194806032382301","journal-title":"N Engl J Med"},{"key":"ref2","article-title":"Methotrexate: a perspective of its use in the treatment of rheumatic diseases","volume":"100","author":"Willkens RF","year":"1982","unstructured":"Willkens RF, Watson MA. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med. 1982, 100:314-21.","journal-title":"J Lab Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt ME","year":"1985","unstructured":"Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985, 312:818-22. 10.1056\/NEJM198503283121303","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.5.748.63584","article-title":"High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?","volume":"25","author":"Mantadakis E","year":"2005","unstructured":"Mantadakis E, Cole PD, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?. Pharmacotherapy. 2005, 25:748-55. 10.1592\/phco.25.5.748.63584","journal-title":"Pharmacotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970048","article-title":"Medical therapy for ectopic pregnancy","volume":"25","author":"Lipscomb GH","year":"2007","unstructured":"Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med. 2007, 25:93-8. 10.1055\/s-2007-970048","journal-title":"Semin Reprod Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo M","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001, 60:729-35. 10.1136\/ard.60.8.729","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066761","article-title":"Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial","volume":"66","author":"Burmester GR","year":"2007","unstructured":"Burmester GR, Mariette X, Montecucco C, et al.. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007, 66:732-9. 10.1136\/ard.2006.066761","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy EH","year":"2005","unstructured":"Choy EH, Smith C, Dor\u00e9 CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford). 2005, 44:1414-21. 10.1093\/rheumatology\/kei031","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07765.x","article-title":"Advances in individual prediction of methotrexate toxicity: a review","volume":"146","author":"Schmiegelow K","year":"2009","unstructured":"Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009, 146:489-503. 10.1111\/j.1365-2141.2009.07765.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1667","article-title":"Patient characteristics associated with high-risk methotrexate concentrations and toxicity","volume":"12","author":"Relling MV","year":"1994","unstructured":"Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994, 12:1667-72. 10.1200\/JCO.1994.12.8.1667","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.12.2017","article-title":"High-dose methotrexate: a critical reappraisal","volume":"5","author":"Ackland SP","year":"1987","unstructured":"Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987, 5:2017-31. 10.1200\/JCO.1987.5.12.2017","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella MA","year":"2010","unstructured":"Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy. Semin Nephrol. 2010, 30:570-81. 10.1016\/j.semnephrol.2010.09.005","journal-title":"Semin Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller RG","year":"1977","unstructured":"Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977, 297:630-4. 10.1056\/NEJM197709222971203","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90477-1","article-title":"Methotrexate therapy in rheumatoid arthritis: 15 years experience","volume":"75","author":"Hoffmeister RT","year":"1983","unstructured":"Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med. 1983, 75:69-73. 10.1016\/0002-9343(83)90477-1","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050404","article-title":"Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment","volume":"53","author":"Chl\u00e1dek J","year":"1998","unstructured":"Chl\u00e1dek J, Mart\u00ednkov\u00e1 J, Simkov\u00e1 M, Vaneckov\u00e1 J, Koudelkov\u00e1 V, Nozickov\u00e1 M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol. 1998, 53:437-44. 10.1007\/s002280050404","journal-title":"Eur J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/42.8.1322","article-title":"Concepts in use of high-dose methotrexate therapy","volume":"42","author":"Treon SP","year":"1996","unstructured":"Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996, 42:1322-9.","journal-title":"Clin Chem"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth B","year":"1996","unstructured":"Bannwarth B, P\u00e9hourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996, 30:194-210. 10.2165\/00003088-199630030-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan ES","year":"2002","unstructured":"Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002, 4:266-73. 10.1186\/ar419","journal-title":"Arthritis Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3310\/hta4400","article-title":"A systematic review of treatments for severe psoriasis","volume":"4","author":"Griffiths CE","year":"2000","unstructured":"Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000, 4:1-125. 10.3310\/hta4400","journal-title":"Health Technol Assess"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.t01-1-00223.x","article-title":"Pneumonitis complicating methotrexate therapy for pustular psoriasis","volume":"15","author":"Ameen M","year":"2001","unstructured":"Ameen M, Taylor DA, Williams IP, Wells AU, Barker JN. Pneumonitis complicating methotrexate therapy for pustular psoriasis. J Eur Acad Dermatol Venereol. 2001, 15:247-9. 10.1046\/j.1468-3083.2001.t01-1-00223.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890260086013","article-title":"Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis","volume":"132","author":"Zonneveld IM","year":"1996","unstructured":"Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol. 1996, 132:184-7. 10.1001\/archderm.1996.03890260086013","journal-title":"Arch Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb02637.x","article-title":"Methotrexate for the treatment of severe mucocutaneous lupus erythematosus","volume":"133","author":"Bottomley WW","year":"1995","unstructured":"Bottomley WW, Goodfield M. Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol. 1995, 133:311-4. 10.1111\/j.1365-2133.1995.tb02637.x","journal-title":"Br J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: revised guidelines","volume":"19","author":"Roenigk HH","year":"1988","unstructured":"Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988, 19:145-56. 10.1016\/S0190-9622(88)80237-8","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5750.625","article-title":"Liver damage due to methotrexate in patients with psoriasis","volume":"1","author":"Dahi MG","year":"1971","unstructured":"Dahi MG, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. Br Med J. 1971, 1:625-30. 10.1136\/bmj.1.5750.625","journal-title":"Br Med J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390030137027","article-title":"Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case-control study of 131 patients","volume":"149","author":"McKendry RJ","year":"1989","unstructured":"McKendry RJ. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case-control study of 131 patients. Arch Intern Med. 1989, 149:685-9. 10.1001\/archinte.1989.00390030137027","journal-title":"Arch Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis JR","year":"2010","unstructured":"Curtis JR, Beukelman T, Onofrei A, et al.. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann Rheum Dis. 2010, 69:43-7. 10.1136\/ard.2008.101378","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer JM","year":"2004","unstructured":"Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004, 50:1370-82. 10.1002\/art.20278","journal-title":"Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262040-00005","article-title":"Drugs affecting homocysteine metabolism: impact on cardiovascular risk","volume":"62","author":"Desouza C","year":"2002","unstructured":"Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs. 2002, 62:605-16. 10.2165\/00003495-200262040-00005","journal-title":"Drugs"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/BF01324802","article-title":"The hepatic stellate (Ito) cell: its role in human liver disease","volume":"430","author":"Hautekeete ML","year":"1997","unstructured":"Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch. 1997, 430:195-207. 10.1007\/BF01324802","journal-title":"Virchows Arch"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259882","article-title":"Hepatotoxicity of methotrexate in rheumatic diseases","volume":"3","author":"Kevat S","year":"1988","unstructured":"Kevat S, Ahern M, Hall P. Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicol Adverse Drug Exp. 1988, 3:197-208. 10.1007\/BF03259882","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094474","article-title":"Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative","volume":"68","author":"Visser K","year":"2009","unstructured":"Visser K, Katchamart W, Loza E, et al.. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009, 68:1086-93. 10.1136\/ard.2008.094474","journal-title":"Ann Rheum Dis"},{"key":"ref32","article-title":"National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study","volume":"30","author":"Thomas E","year":"2003","unstructured":"Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003, 30:958-65.","journal-title":"J Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20471","article-title":"Methotrexate induces cell swelling and necrosis in renal tubular cells","volume":"46","author":"Gr\u00f6nroos M","year":"2006","unstructured":"Gr\u00f6nroos M, Chen M, Jahnukainen T, Capitanio A, Aizman RI, Celsi G. Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatr Blood Cancer. 2006, 46:624-9. 10.1002\/pbc.20471","journal-title":"Pediatr Blood Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/toxins2082055","article-title":"Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity","volume":"2","author":"Hagos Y","year":"2010","unstructured":"Hagos Y, Wolff NA. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel). 2010, 2:2055-82. 10.3390\/toxins2082055","journal-title":"Toxins (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12282","article-title":"Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development","volume":"77","author":"van Meer L","year":"2014","unstructured":"van Meer L, Moerland M, Cohen AF, Burggraaf J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol. 2014, 77:947-57. 10.1111\/bcp.12282","journal-title":"Br J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson HT","year":"1983","unstructured":"Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, Link D. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol. 1983, 1:208-16. 10.1200\/JCO.1983.1.3.208","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0301-7","article-title":"Low-dose methotrexate-induced pancytopenia","volume":"26","author":"Preet Singh Y","year":"2007","unstructured":"Preet Singh Y, Aggarwal A, Misra R, Agarwal V. Low-dose methotrexate-induced pancytopenia. Clin Rheumatol. 2007, 26:84-7. 10.1007\/s10067-006-0301-7","journal-title":"Clin Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Ure\u00f1a S","year":"1996","unstructured":"Gutierrez-Ure\u00f1a S, Molina JF, Garc\u00eda CO, Cu\u00e9llar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996, 39:272-6. 10.1002\/art.1780390214","journal-title":"Arthritis Rheum"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2792-2","article-title":"Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study","volume":"33","author":"Pamuk ON","year":"2013","unstructured":"Pamuk ON, Kisacik B, Pamuk GE, et al.. Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study. Rheumatol Int. 2013, 33:2631-5. 10.1007\/s00296-013-2792-2","journal-title":"Rheumatol Int"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127558","article-title":"Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-acetylcysteine and N-acetylcysteine amide","volume":"10","author":"Paul M","year":"2015","unstructured":"Paul M, Hemshekhar M, Thushara RM, et al.. Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-acetylcysteine and N-acetylcysteine amide. PLoS One. 2015, 10:e0127558. 10.1371\/journal.pone.0127558","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181a61f2d","article-title":"Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate","volume":"15","author":"Cheung KK","year":"2009","unstructured":"Cheung KK, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK. Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol. 2009, 15:177-80. 10.1097\/RHU.0b013e3181a61f2d","journal-title":"J Clin Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.23.6.480","article-title":"An association between the rheumatic diseases and the reticuloses","volume":"23","author":"Lea AJ","year":"1964","unstructured":"Lea AJ. An association between the rheumatic diseases and the reticuloses. Ann Rheum Dis. 1964, 23:480-4. 10.1136\/ard.23.6.480","journal-title":"Ann Rheum Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70387-1","article-title":"Thrombocytopenia after a single test dose of methotrexate","volume":"39","author":"Jih DM","year":"1998","unstructured":"Jih DM, Werth VP. Thrombocytopenia after a single test dose of methotrexate. J Am Acad Dermatol. 1998, 39:349-51. 10.1016\/S0190-9622(98)70387-1","journal-title":"J Am Acad Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep101","article-title":"Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?","volume":"48","author":"McLean-Tooke A","year":"2009","unstructured":"McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. Rheumatology (Oxford). 2009, 48:867-71. 10.1093\/rheumatology\/kep101","journal-title":"Rheumatology (Oxford)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon DH","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW, et al.. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020, 172:369-80. 10.7326\/M19-3369","journal-title":"Ann Intern Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway R","year":"2014","unstructured":"Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014, 66:803-12. 10.1002\/art.38322","journal-title":"Arthritis Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2008.11.016","article-title":"Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway","volume":"256","author":"Kim YJ","year":"2009","unstructured":"Kim YJ, Song M, Ryu JC. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology. 2009, 256:183-90. 10.1016\/j.tox.2008.11.016","journal-title":"Toxicology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0578-7","article-title":"Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis","volume":"17","author":"Cho I","year":"2007","unstructured":"Cho I, Mori S, Imamura F, Kiyofuji C, Sugimoto M. Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis. Mod Rheumatol. 2007, 17:256-61. 10.3109\/s10165-007-0578-7","journal-title":"Mod Rheumatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2131\/jts.35.653","article-title":"Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro","volume":"35","author":"Ohbayashi M","year":"2010","unstructured":"Ohbayashi M, Suzuki M, Yashiro Y, et al.. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. J Toxicol Sci. 2010, 35:653-61. 10.2131\/jts.35.653","journal-title":"J Toxicol Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study","volume":"127","author":"Alarc\u00f3n GS","year":"1997","unstructured":"Alarc\u00f3n GS, Kremer JM, Macaluso M, et al.. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Ann Intern Med. 1997, 127:356-64. 10.7326\/0003-4819-127-5-199709010-00003","journal-title":"Ann Intern Med"},{"key":"ref51","article-title":"The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis","volume":"22","author":"Golden MR","year":"1995","unstructured":"Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995, 22:1043-7.","journal-title":"J Rheumatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2012.11.010","article-title":"Protective effects of sweroside on human MG-63 cells and rat osteoblasts","volume":"84","author":"Sun H","year":"2013","unstructured":"Sun H, Li L, Zhang A, Zhang N, Lv H, Sun W, Wang X. Protective effects of sweroside on human MG-63 cells and rat osteoblasts. Fitoterapia. 2013, 84:174-9. 10.1016\/j.fitote.2012.11.010","journal-title":"Fitoterapia"},{"key":"ref53","article-title":"Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis","volume":"18","author":"Singh G","year":"1991","unstructured":"Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991, 18:188-94.","journal-title":"J Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90517-1","article-title":"Cryptococcosis associated with low-dose methotrexate for arthritis","volume":"83","author":"Altz-Smith M","year":"1987","unstructured":"Altz-Smith M, Kendall LG, Stamm AM. Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med. 1987, 83:179-81. 10.1016\/0002-9343(87)90517-1","journal-title":"Am J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380222","article-title":"Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis","volume":"38","author":"Aglas F","year":"1995","unstructured":"Aglas F, Rainer F, Hermann J, Gretler J, H\u00fcttl E, Domej W, Krejs GJ. Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis. Arthritis Rheum. 1995, 38:291-2. 10.1002\/art.1780380222","journal-title":"Arthritis Rheum"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2013.09.013","article-title":"Epstein-Barr virus-positive oral ulceration simulating Hodgkin lymphoma in a patient treated with methotrexate: case report and review of the literature","volume":"72","author":"Naidu A","year":"2014","unstructured":"Naidu A, Kessler HP, Pavelka MA. Epstein-Barr virus-positive oral ulceration simulating Hodgkin lymphoma in a patient treated with methotrexate: case report and review of the literature. J Oral Maxillofac Surg. 2014, 72:724-9. 10.1016\/j.joms.2013.09.013","journal-title":"J Oral Maxillofac Surg"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky S","year":"2007","unstructured":"Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007, 46:1157-60. 10.1093\/rheumatology\/kem076","journal-title":"Rheumatology (Oxford)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2016.12.012","article-title":"Methotrexate-associated primary hepatic malignant lymphoma following hepatectomy: a case report","volume":"31","author":"Takei D","year":"2017","unstructured":"Takei D, Abe T, Amano H, et al.. Methotrexate-associated primary hepatic malignant lymphoma following hepatectomy: a case report. Int J Surg Case Rep. 2017, 31:5-9. 10.1016\/j.ijscr.2016.12.012","journal-title":"Int J Surg Case Rep"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot C","year":"2009","unstructured":"Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009, 68:1100-4. 10.1136\/ard.2008.093690","journal-title":"Ann Rheum Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1159\/000314634","article-title":"Malignancies in autoimmune rheumatic diseases: a mini-review","volume":"57","author":"Szekanecz Z","year":"2011","unstructured":"Szekanecz Z, Szekanecz E, Bak\u00f3 G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases: a mini-review. Gerontology. 2011, 57:3-10. 10.1159\/000314634","journal-title":"Gerontology"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \"methotrexate-associated lymphoproliferative disorders\" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi R","year":"2009","unstructured":"Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, Liso V. Spontaneous remission of \"methotrexate-associated lymphoproliferative disorders\" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2009, 26:1-9. 10.1007\/s12032-008-9069-8","journal-title":"Med Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.02.002","article-title":"Methotrexate-induced CD30(+) T-cell lymphoproliferative disorder of the oral cavity","volume":"2","author":"Saleh JZ","year":"2016","unstructured":"Saleh JZ, Lee LH, Schieke SM, Hosking PR, Hwang ST. Methotrexate-induced CD30(+) T-cell lymphoproliferative disorder of the oral cavity. JAAD Case Rep. 2016, 2:354-6. 10.1016\/j.jdcr.2016.02.002","journal-title":"JAAD Case Rep"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1159\/000249793","article-title":"Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study","volume":"167","author":"Nyfors A","year":"1983","unstructured":"Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study. Dermatologica. 1983, 167:260-1. 10.1159\/000249793","journal-title":"Dermatologica"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70199-C","article-title":"The pharmacology of methotrexate","volume":"25","author":"Olsen EA","year":"1991","unstructured":"Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991, 25:306-18. 10.1016\/0190-9622(91)70199-C","journal-title":"J Am Acad Dermatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial","volume":"121","author":"Morgan SL","year":"1994","unstructured":"Morgan SL, Baggott JE, Vaughn WH, et al.. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med. 1994, 121:833-41. 10.7326\/0003-4819-121-11-199412010-00002","journal-title":"Ann Intern Med"},{"key":"ref66","doi-asserted-by":"crossref","DOI":"10.5070\/D34JG110CW","article-title":"Focal skin toxicity related to methotrexate sparing psoriatic plaques","volume":"16","author":"Truchuelo T","year":"2010","unstructured":"Truchuelo T, Alc\u00e1ntara J, Moreno C, Vano-Galv\u00e1n S, Ja\u00e9n P. Focal skin toxicity related to methotrexate sparing psoriatic plaques. Dermatol Online J. 2010, 16:16.","journal-title":"Dermatol Online J"},{"key":"ref67","article-title":"Mucocutaneous ulcerations secondary to methotrexate","volume":"81","author":"Warner J","year":"2008","unstructured":"Warner J, Brown A, Whitmore SE, Cowan DA. Mucocutaneous ulcerations secondary to methotrexate. Cutis. 2008, 81:413-6.","journal-title":"Cutis"},{"key":"ref68","doi-asserted-by":"crossref","DOI":"10.5070\/D381Q6R16G","article-title":"Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: a diagnostic clue","volume":"17","author":"Fridlington JL","year":"2011","unstructured":"Fridlington JL, Tripple JW, Reichenberg JS, Hall CS, Diven DG. Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: a diagnostic clue. Dermatol Online J. 2011, 17:2.","journal-title":"Dermatol Online J"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler WJ","year":"2011","unstructured":"Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011, 127:S74-81. 10.1016\/j.jaci.2010.11.048","journal-title":"J Allergy Clin Immunol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/946716","article-title":"Acute methotrexate toxicity: a fatal condition in two cases of psoriasis","volume":"2014","author":"Jariwala P","year":"2014","unstructured":"Jariwala P, Kumar V, Kothari K, Thakkar S, Umrigar DD. Acute methotrexate toxicity: a fatal condition in two cases of psoriasis. Case Rep Dermatol Med. 2014, 2014:946716. 10.1155\/2014\/946716","journal-title":"Case Rep Dermatol Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference","volume":"60","author":"Kalb RE","year":"2009","unstructured":"Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009, 60:824-37. 10.1016\/j.jaad.2008.11.906","journal-title":"J Am Acad Dermatol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(84)70259-3","article-title":"Two patterns of skin ulceration induced by methotrexate in patients with psoriasis","volume":"11","author":"Lawrence CM","year":"1984","unstructured":"Lawrence CM, Dahl MG. Two patterns of skin ulceration induced by methotrexate in patients with psoriasis. J Am Acad Dermatol. 1984, 11:1059-65. 10.1016\/S0190-9622(84)70259-3","journal-title":"J Am Acad Dermatol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1973.190","article-title":"Methotrexate in liver and bile after intravenous dosage in man","volume":"28","author":"Creaven PJ","year":"1973","unstructured":"Creaven PJ, Hansen HH, Alford DA, Allen LM. Methotrexate in liver and bile after intravenous dosage in man. Br J Cancer. 1973, 28:589-91. 10.1038\/bjc.1973.190","journal-title":"Br J Cancer"},{"key":"ref74","article-title":"A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue","volume":"39","author":"Stoller RG","year":"1979","unstructured":"Stoller RG, Kaplan HG, Cummings FJ, Calabresi P. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res. 1979, 39:908-12.","journal-title":"Cancer Res"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118","article-title":"A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis","volume":"28","author":"Mrowietz U","year":"2014","unstructured":"Mrowietz U, de Jong EM, Kragballe K, et al.. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014, 28:438-53. 10.1111\/jdv.12118","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_157_18","article-title":"Acute methotrexate toxicity due to overdosing in psoriasis: a series of seven cases","volume":"10","author":"Pradhan S","year":"2019","unstructured":"Pradhan S, Sirka CS, Rout AN, Dash G, Sahu K. Acute methotrexate toxicity due to overdosing in psoriasis: a series of seven cases. Indian Dermatol Online J. 2019, 10:64-8. 10.4103\/idoj.IDOJ_157_18","journal-title":"Indian Dermatol Online J"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045221","article-title":"Dietary transforming growth factor-beta 2 (TGF-\u03b22) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat","volume":"7","author":"Ben-Lulu S","year":"2012","unstructured":"Ben-Lulu S, Pollak Y, Mogilner J, Bejar J, Coran AG, Sukhotnik I. Dietary transforming growth factor-beta 2 (TGF-\u03b22) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat. PLoS One. 2012, 7:e45221. 10.1371\/journal.pone.0045221","journal-title":"PLoS One"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.5032","article-title":"Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine","volume":"28","author":"Zhang A","year":"2014","unstructured":"Zhang A, Sun H, Wang X. Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine. Phytother Res. 2014, 28:526-33. 10.1002\/ptr.5032","journal-title":"Phytother Res"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun J","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, et al.. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008, 58:73-81. 10.1002\/art.23144","journal-title":"Arthritis Rheum"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1159\/000356817","article-title":"Life-threatening gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis","volume":"7","author":"Tsukada T","year":"2013","unstructured":"Tsukada T, Nakano T, Miyata T, Sasaki S. Life-threatening gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis. Case Rep Gastroenterol. 2013, 7:470-5. 10.1159\/000356817","journal-title":"Case Rep Gastroenterol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.244","article-title":"SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients","volume":"15","author":"Lima A","year":"2014","unstructured":"Lima A, Bernardes M, Sousa H, et al.. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2014, 15:807-20. 10.2217\/pgs.13.244","journal-title":"Pharmacogenomics"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/XXXIV.suppl_4.20","article-title":"Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis","volume":"XXXIV","author":"Furst DE","year":"1995","unstructured":"Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Rheumatology. 1995, XXXIV:20-5. 10.1093\/rheumatology\/XXXIV.suppl_4.20","journal-title":"Rheumatology"},{"key":"ref83","article-title":"Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport","volume":"51","author":"Matherly LH","year":"1991","unstructured":"Matherly LH, Czajkowski CA, Angeles SM. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res. 1991, 51:3420-6.","journal-title":"Cancer Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06395-3","article-title":"Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort","volume":"30","author":"Niinim\u00e4ki R","year":"2022","unstructured":"Niinim\u00e4ki R, Aarnivala H, Banerjee J, Pokka T, Veps\u00e4l\u00e4inen K, Harila-Saari A. Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort. Support Care Cancer. 2022, 30:127-33. 10.1007\/s00520-021-06395-3","journal-title":"Support Care Cancer"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110467","article-title":"Folinic acid over rescue of high dose methotrexate: how problematic citations conserve discredited concepts","volume":"146","author":"Cohen IJ","year":"2021","unstructured":"Cohen IJ. Folinic acid over rescue of high dose methotrexate: how problematic citations conserve discredited concepts. Med Hypotheses. 2021, 146:110467. 10.1016\/j.mehy.2020.110467","journal-title":"Med Hypotheses"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann BC","year":"2006","unstructured":"Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006, 11:694-703. 10.1634\/theoncologist.11-6-694","journal-title":"Oncologist"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard SC","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016, 21:1471-82. 10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"ref88","article-title":"Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity","volume":"38","author":"Rattu MA","year":"2013","unstructured":"Rattu MA, Shah N, Lee JM, Pham AQ, Marzella N. Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. P T. 2013, 38:732-44.","journal-title":"P T"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki K","year":"2009","unstructured":"Suzuki K, Doki K, Homma M, et al.. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009, 67:44-9. 10.1111\/j.1365-2125.2008.03303.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag KG","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, et al.. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008, 59:762-84. 10.1002\/art.23721","journal-title":"Arthritis Rheum"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1002\/art.20167","article-title":"Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial","volume":"50","author":"Lambert CM","year":"2004","unstructured":"Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum. 2004, 50:364-71. 10.1002\/art.20167","journal-title":"Arthritis Rheum"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(95)90010-1","article-title":"Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function","volume":"21","author":"Kintzel PE","year":"1995","unstructured":"Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995, 21:33-64. 10.1016\/0305-7372(95)90010-1","journal-title":"Cancer Treat Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/114596-overview-of-methotrexate-toxicity-a-comprehensive-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:41Z","timestamp":1707508121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/114596-overview-of-methotrexate-toxicity-a-comprehensive-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":92,"URL":"https:\/\/doi.org\/10.7759\/cureus.29518","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}